(Q30353872)

20 June 2017

title

New and emerging drug molecules against obesity. (English)

1 reference

20 June 2017

0 references

Melvin George

1

0 references

author name string

Muthukumar Rajaram

series ordinal

2

1 reference

20 June 2017

Elangovan Shanmugam

series ordinal

3

1 reference

20 June 2017

publication date

24 September 2013

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

20 June 2017

published in

1 reference

20 June 2017

volume

19

1 reference

20 June 2017

issue

1

1 reference

20 June 2017

page(s)

65-76

1 reference

Current estimates of the economic cost of obesity in the United States

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Systematic prevention of overweight and obesity in adults: a qualitative and quantitative literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Orlistat-associated adverse effects and drug interactions: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Long-term use of diethylpropion in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Safety of drug therapies used for weight loss and treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Pharmacological treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

New drug targets for the treatment of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Tesofensine – a novel potent weight loss medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Lower pleasantness of palatable foods in nalmefene-treated human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Opioid peptides and the control of human ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Central and peripheral molecular targets for antiobesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Angiogenesis in Adipose Tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Angiogenesis and development of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

21 January 2018

Angiogenesis and obesity

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Angiogenic factors are elevated in overweight and obese individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

The obesity pipeline: current strategies in the development of anti-obesity drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Phenylpropanolamine and the risk of hemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Obesity paradox in patients with hypertension and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Value of weight reduction in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Depression and anxiety with rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248413501017

21 January 2018

Identifiers

DOI

10.1177/1074248413501017

1 reference

20 June 2017

1 reference